Scoop: Sanofi qui­et­ly ties up with a low-pro­file, pre­clin­i­cal can­cer biotech — FTC signs off

Sanofi CEO Paul Hud­son is build­ing up the on­col­o­gy cup­board.

The FTC not­ed on Tues­day that it has ap­proved a deal be­tween Sanofi — list­ed as the “ac­quir­ing par­ty” — and Nurix Ther­a­peu­tics, the “ac­quired par­ty.” The tie-up has nev­er been men­tioned pub­licly.

A spokesper­son for Sanofi tells me via e-mail that the two com­pa­nies have a re­search col­lab­o­ra­tion they plan to spot­light next week at JP Mor­gan, with Nurix ex­ecs ex­pect­ed to of­fer more de­tails in the days to come. A rep­re­sen­ta­tive of the biotech con­firmed that they would be out­lin­ing the al­liance next week.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER